March 27th 2023
In an interview, Edwin Choy, MD, discussed the treatment landscape of GIST and recent changes to NCCN guidelines.
Pimitespib Shows Significant PFS Improvement in Advanced Refractory GIST
June 8th 2021Pimitespib, a heat shock protein 90 inhibitor doubled the progression-free survival and prolonged the overall survival compared with placebo in patients with advanced gastrointestinal stromal tumor that is refractory to imatinib, sunitinib, and regorafenib, according to results from the phase 3 CHAPTER-GIST-301 trial.
Read More
Increased Dose of Ripretinib Improves Survival in Heavily Pretreated Advanced GIST
June 4th 2021Patients with advanced gastrointestinal stromal tumor after receiving fourth-line therapy had extended progression-free survival when given an intra-patient dose escalation of ripretinib to 150 mg twice a day following progression.
Read More
More Benefit Observed With Avapritinib Than Other TKIs in Mutated GIST
May 21st 2021A retrospective analysis showed there were more durable survival outcomes with avapritinib versus other tyrosine kinase inhibitors in adult patients with gastrointestinal stromal tumors and a platelet-derived growth factor receptor A D842V mutation
Read More
Precision Medicine Stakes Claim in the Gastrointestinal Stromal Tumors Landscape
March 9th 2021In an interview with Targeted Oncology, Margaret von Mehren, MD, reviews the recent advancements in the GIST treatment landscape. She also explains what’s needed to move the needle further in the future.
Read More
Adjuvant Imatinib Confirmed Beneficial for RFS in High-Risk Gastrointestinal Stromal Tumors
February 20th 2021Adjuvant imatinib has demonstrated significant improvement in relapse-free survival over a 2-year period and a mild trend toward long-term improvement in failure-free survival as treatment of patients with high-risk gastrointestinal stromal tumors, according to 9.1-year follow-up results from a randomized phase 3 study.
Read More
FDA-Approved Advanced GIST Therapy Can Elicit Durable Responses With Tolerable Safety
February 20th 2021In patients with gastrointestinal stromal tumors who have received 3 or more prior therapies, there remain unmet needs to overcome resistance to the standard-of-care, imatinib, a tyrosine kinase inhibitor, and prolong the 6.3-month+ progression-free survival achieved with the FDA-approved TKI ripretinib.
Read More
Invasive GIST Originating in the Stomach/Small Intestine Is More Common in Men, Study Shows
February 19th 2021Men appear to be more likely than women to have invasive gastrointestinal stromal tumors originating in the stomach and small intestines. For treatment, an expert says that combined surgery and systemic therapy demonstrates the best outcomes.
Read More
Continued PFS, OS Benefit Seen With Ripretinib in Advanced GIST
September 19th 2020For patients with advanced gastrointestinal stromal tumors, there was continued clinically meaningful benefit with the novel broad-spectrum KIT and PDGFRα inhibitor ripretinib in the fourth line or later, according to updated data from the randomized phase 3 INVICTUS trial presented at the 2020 ESMO Virtual Congress.
Read More
Binimetinib Added to Standard of Care Elicits Responses in Advanced GIST
July 20th 2020In an interview with Targeted Oncology, Ping Chi, MD medical oncologist, Geoffrey Beene Junior Faculty chair, Memorial Sloan Kettering Cancer Center, discussed the phase 2 study of binimetinib in combination with imatinib in patients with untreated advanced GIST.
Read More